Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


With the Comprehensive Spending Review, Osborne Gets Personal

8 July 2013

By Stephen Caddick, Vice-Provost (Enterprise) at UCL

This time, the Comprehensive Spending Review is personal. George Osborne has gone public with his personal commitment to science at a recent visit to the site of the Francis Crick Institute, and following that there's been widespread speculation about how far that commitment will stretch.

Read the full article at huffingtonpost.co.uk